Please login to the form below

Not currently logged in
Email:
Password:

Merck Serono adds Japan to Aurora kinase collaboration

Merck Serono exercises its option to add the Japanese territory to its current Aurora kinase collaboration which includes the lead product, R763/AS703569

Merck Serono, a division of German-based Merck KGaA, has exercised its option to add the Japanese territory to its current Aurora kinase collaboration which includes the lead product, R763/AS703569.

In exchange for these extended development and marketing rights, co-development partner US-based pharmaceutical company Rigel will receive a USD 3m payment.

In October 2005, the two companies entered into a worldwide collaboration, excluding Japan, to develop R763/AS703569 and other Aurora kinase inhibitors. As part of this agreement, Merck Serono had the right to add Japan to its territory.

R763/AS703569 is an oral, highly potent inhibitor of Aurora kinases and has exhibited anti-tumour activity against a broad range of cancer cell lines. To date, three phase I clinical trials with R763/AS703569, sponsored by Merck Serono, have been initiated and are ongoing in patients with solid tumors and leukemia.

If proven safe and efficacious, this regimen could dramatically alter the lives of patients with a variety of cancers including pancreatic, ovarian, breast, non-small cell lung and colorectal, as well as those with hematological malignancies.

Rigel's CEO Raul Rodriguez said: "Developing a novel, effective, oral therapeutic for cancer patients is the primary goal of our Aurora kinase collaboration with Merck Serono. We are proud that Merck Serono has re-affirmed its commitment to this programme."

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics